Compare DexCom, Inc. (DXCM) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs TJX Companies Inc — how do they compare? DexCom, Inc. trades at $76.86 (market cap $28.06B), while TJX Companies Inc trades at $151.21 (market cap $166.78B). The key difference: TJX Companies Inc is far larger — about 5.9× DexCom, Inc.'s market cap, and TJX Companies Inc pays a 1.27% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | TJX | |
|---|---|---|
Market Cap | $28.06B | $166.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $168.41 |
52-Week Low | $54.84 | $121.35 |
Enterprise Value | $27.03B | $175.38B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
TJX Companies (TJX) trades at $154.81, up 2.97% today, with strong earnings beats in recent quarters. The stock shows a bullish fundamental profile with 9.4% net income margin and 61.25% ROE, though technical indicators signal near-term bearish pressure. Revenue growth accelerated to $56.36B in 2025, with analyst consensus strongly favoring Buy ratings (88.46%). Recent news highlights TJX as a defensive retail play during economic uncertainty, with expansion in international markets like Europe and Australia.
Outlook remains positive given consistent earnings outperformance and robust cash flow, but valuation multiples (P/E 29.37) suggest premium pricing. Key risks include consumer spending volatility and competitive pressures. Wall Street's average price target of $181.80 implies ~17% upside, supported by institutional confidence and dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
